Ignite Creation Date:
2024-05-06 @ 5:53 PM
Last Modification Date:
2024-10-26 @ 2:37 PM
Study NCT ID:
NCT05461807
Status:
COMPLETED
Last Update Posted:
2022-10-26
First Post:
2022-07-14
Brief Title:
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins Venous Thromboembolism
Sponsor:
Bayer
Organization:
Bayer
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-14
Start Date Type:
ACTUAL
Primary Completion Date:
2022-10-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-05
Completion Date Type:
ACTUAL
First Submit Date:
2022-07-14
First Submit QC Date:
July 14 2022
Study First Post Date:
2022-07-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-10-25
Last Update Post Date:
2022-10-26
Last Update Post Date Type:
ACTUAL